Drugs / OXA
last change Jul 2026 re-read 2 minutes ago

OXA

Developed for
gastric cancer
Investigated by
Xijing Hospital

Trials 1 · a red edge is where a trial was stopped

20252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT06459921 Dec 2024 → Jul 2026 overdue gastric cancer Xijing Hospital Not yet recruiting No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as OXA “day 1: intravenous 5-FU 2600 mg/m² inserted through a peripherally inserted central catheter (PICC) for 24 hours intravenous folic acid 200 mg/m2 intravenous OXA 85 mg/m²...” NCT06459921
Route Intravenous intravenous OXA 85 mg/m²” NCT06459921